Search
evacetrapib
Investigational drug.
Indications:
- dyslipidemia
- coronary artery disease
Dosage:
- 100-500 mg QD
- 100 mg QD when used in combination with statin
Mechanism of action:
- CETP inhibitor
- increases HDL cholesterol, lowers LDL cholesterol
- no reduction in cardiovascular events or mortality in high-risk patients [2]
Interactions
drug adverse effects of anti-hyperlipidemic agents
General
anti-hyperlipidemic agent
References
- Nicholls SJ et al.
Effects of the CETP inhibitor evacetrapib administered as
monotherapy or in combination with statins on HDL and LDL
cholesterol.
JAMA 2011 Nov 16; 306:2099.
PMID: 22089718
http://jama.ama-assn.org/content/306/19/2099.full
- Cannon CP.
High-density lipoprotein cholesterol as the holy grail.
JAMA 2011 Nov 16; 306:2153.
PMID: 22089726
- Lincoff AM, Nicholls SJ, Riesmeyer JS et al.
Evacetrapib and cardiovascular outcomes in high-risk vascular
disease.
N Engl J Med 2017 May 18; 376:1933.
PMID: 28514624
http://www.nejm.org/doi/10.1056/NEJMoa1609581